MX2022002433A - Análogos de compstatina y sus usos médicos. - Google Patents
Análogos de compstatina y sus usos médicos.Info
- Publication number
- MX2022002433A MX2022002433A MX2022002433A MX2022002433A MX2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A MX 2022002433 A MX2022002433 A MX 2022002433A
- Authority
- MX
- Mexico
- Prior art keywords
- compstatin
- analogues
- introduction
- complement
- inhibiting activity
- Prior art date
Links
- RDTRHBCZFDCUPW-KWICJJCGSA-N 2-[(4r,7s,10s,13s,19s,22s,25s,28s,31s,34r)-4-[[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]carbamoyl]-34-[[(2s,3s)-2-amino-3-methylpentanoyl]amino]-25-(3-amino-3-oxopropyl)-7-[3-(diaminomethylideneamino)propyl]-10,13-bis(1h-imidazol-5-ylmethyl)-19-(1h-indol Chemical class C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CSSC[C@@H](C(N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N1)C(C)C)C(C)C)=O)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)C1=CN=CN1 RDTRHBCZFDCUPW-KWICJJCGSA-N 0.000 title abstract 4
- 108010027437 compstatin Proteins 0.000 abstract 3
- 229940024606 amino acid Drugs 0.000 abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
Abstract
Se describen análogos de compstatina que presentan una actividad de unión e inhibición del complemento mejorada en comparación con el péptido de compstatina de 13 aminoácidos (ICWQDWGHHRCT (C2-C12 cíclico)), en particular análogos de compstatina que además poseen propiedades fisicoquímicas útiles. Los análogos tienen un enlace de tipo tioéter en lugar de un enlace de tipo disulfuro entre las cadenas laterales de los residuos correspondientes a las cisteínas 2 y 12 de la compstatina, lo que puede aumentar su estabilidad. Los análogos también pueden tener un residuo de isoleucina en la posición 3 en lugar del residuo de valina de origen natural, lo que proporciona a los péptidos de compstatina una actividad mejorada de unión y de inhibición del complemento y también permite la introducción de otras modificaciones, por ejemplo, modificaciones que son capaces de aumentar la solubilidad tales como la introducción de aminoácidos cargados o polares en la posición 9 y/o la introducción de secuencias N- y/o C-terminales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19193925 | 2019-08-27 | ||
| EP20172189 | 2020-04-29 | ||
| PCT/EP2020/073905 WO2021037942A1 (en) | 2019-08-27 | 2020-08-26 | Compstatin analogues and their medical uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002433A true MX2022002433A (es) | 2022-05-19 |
Family
ID=72178552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002433A MX2022002433A (es) | 2019-08-27 | 2020-08-26 | Análogos de compstatina y sus usos médicos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220306695A1 (es) |
| EP (2) | EP4272751A3 (es) |
| KR (1) | KR20220066287A (es) |
| CN (1) | CN114630836A (es) |
| AU (1) | AU2020338688A1 (es) |
| BR (1) | BR112022003760A2 (es) |
| CA (1) | CA3148536A1 (es) |
| CO (1) | CO2022003556A2 (es) |
| IL (1) | IL290858A (es) |
| MX (1) | MX2022002433A (es) |
| TW (1) | TW202128731A (es) |
| WO (1) | WO2021037942A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2020128624A (ru) * | 2018-02-27 | 2022-03-28 | Зп Спв 3 К/С | Аналоги компстатина и их медицинское применение |
| IL304214B2 (en) | 2021-01-20 | 2025-01-01 | Viking Therapeutics Inc | Compositions and methods for treating metabolic and liver disorders |
| WO2023048151A1 (ja) * | 2021-09-22 | 2023-03-30 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する環状ペプチド |
| WO2024110878A1 (en) * | 2022-11-24 | 2024-05-30 | Amyndas Pharmaceuticals Us Llc | Compstatin analogs for vector-based therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2248772C (en) | 1996-03-13 | 2007-06-12 | John D. Lambris | Novel peptides which inhibit complement activation |
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| CZ295838B6 (cs) | 1996-09-09 | 2005-11-16 | Zealand Pharma A/S | Způsob výroby peptidů |
| WO1999013899A1 (en) * | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| EP1956000B1 (en) | 1999-03-17 | 2016-10-05 | Novo Nordisk A/S | Acylating agents useful for acylating peptides |
| SI1549333T1 (sl) | 2002-09-20 | 2012-02-29 | Univ Pennsylvania | Analogi kompstatina z izboljĺ ano aktivnostjo |
| CN103505718B (zh) | 2005-10-08 | 2018-11-23 | 阿佩利斯制药公司 | 用于眼部病症的补体抑制素和其类似物 |
| RS52429B (en) | 2005-11-28 | 2013-02-28 | The Trustees Of The University Of Pennsylvania | POTENTIAL ANALYSIS OF COMPSTATIN |
| WO2008153963A1 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennsylvania | Structure of compstatin-c3 complex and use for rational drug design |
| WO2010039690A1 (en) * | 2008-09-30 | 2010-04-08 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
| WO2012040259A2 (en) * | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| HUE047375T2 (hu) | 2011-09-07 | 2020-04-28 | Univ Pennsylvania | Javított farmakokinetikai tulajdonságokkal rendelkezõ compstatin analógok |
| US9512180B2 (en) * | 2012-12-19 | 2016-12-06 | The Regents Of The University Of California | Compstatin analogs |
| AR099569A1 (es) * | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| US20180057538A1 (en) * | 2016-08-26 | 2018-03-01 | The Regents Of The University Of California | Potent and highly soluble pegylated compstatin peptides |
| RU2020128624A (ru) * | 2018-02-27 | 2022-03-28 | Зп Спв 3 К/С | Аналоги компстатина и их медицинское применение |
-
2020
- 2020-08-26 EP EP23192007.5A patent/EP4272751A3/en active Pending
- 2020-08-26 CA CA3148536A patent/CA3148536A1/en active Pending
- 2020-08-26 CN CN202080067713.3A patent/CN114630836A/zh active Pending
- 2020-08-26 KR KR1020227010019A patent/KR20220066287A/ko active Pending
- 2020-08-26 WO PCT/EP2020/073905 patent/WO2021037942A1/en active Application Filing
- 2020-08-26 US US17/637,392 patent/US20220306695A1/en active Pending
- 2020-08-26 BR BR112022003760A patent/BR112022003760A2/pt unknown
- 2020-08-26 AU AU2020338688A patent/AU2020338688A1/en active Pending
- 2020-08-26 EP EP20760472.9A patent/EP4021921A1/en active Pending
- 2020-08-26 MX MX2022002433A patent/MX2022002433A/es unknown
- 2020-08-27 TW TW109129392A patent/TW202128731A/zh unknown
-
2022
- 2022-02-23 IL IL290858A patent/IL290858A/en unknown
- 2022-03-25 CO CONC2022/0003556A patent/CO2022003556A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL290858A (en) | 2022-04-01 |
| WO2021037942A1 (en) | 2021-03-04 |
| BR112022003760A2 (pt) | 2022-05-31 |
| KR20220066287A (ko) | 2022-05-24 |
| EP4272751A3 (en) | 2024-02-14 |
| CA3148536A1 (en) | 2021-03-04 |
| AU2020338688A1 (en) | 2022-03-24 |
| TW202128731A (zh) | 2021-08-01 |
| CN114630836A (zh) | 2022-06-14 |
| US20220306695A1 (en) | 2022-09-29 |
| EP4272751A2 (en) | 2023-11-08 |
| CO2022003556A2 (es) | 2022-05-20 |
| EP4021921A1 (en) | 2022-07-06 |
| JP2022545916A (ja) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002433A (es) | Análogos de compstatina y sus usos médicos. | |
| MX2020008902A (es) | Analogos de compstatina y sus usos medicos. | |
| EP4467650A3 (en) | Scaffold proteins | |
| MX2009012675A (es) | Tensioactivos reconstituidos que tienen propiedades mejoradas. | |
| EP2476697A3 (en) | Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| MX2023000679A (es) | Inhibidores del factor c3 del complemento y sus usos medicos. | |
| EA200901108A1 (ru) | Соагонисты глюкагоновых/glp-1-рецепторов | |
| CA2651990C (en) | Improved antimicrobial peptides | |
| BR112022012057A2 (pt) | Novos métodos de entrega celular | |
| WO2018215525A8 (en) | Mic-1 compounds and uses thereof | |
| MX2021001507A (es) | Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer. | |
| WO2019148195A3 (en) | Cyclic peptidyl inhibitors of cal-pdz binding domain | |
| MY205028A (en) | Protein for treatment of inflammatory diseases | |
| MX2020010520A (es) | Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas. | |
| MX2023011194A (es) | Peptido y composicion que contiene peptido. | |
| ZA202210882B (en) | Anti-fungal polypeptides | |
| ATE551353T1 (de) | Protein mit fusogener wirkung, nukleinsäuresequenzen, die für dieses protein codieren und pharmazeutische zusammensetzungen, die dieses enthalten | |
| WO2017211922A3 (en) | Protease-resistant mono-lipidated peptides | |
| WO2009038729A3 (en) | Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen | |
| WO2005074626A3 (en) | Compositions, methods and uses for a novel family of peptides | |
| WO2015110809A3 (en) | Drug delivery system | |
| EP4403566A3 (en) | Peptides with vasodilatory and/or diuretic functions | |
| NZ706202A (en) | Peptide antagonists of the vasopressin-2 receptor | |
| EP4414384A3 (en) | A recombinant protein |